Breaking News Instant updates and real-time market news.

GILD

Gilead

$64.31

-0.38 (-0.59%)

10:55
05/25/17
05/25
10:55
05/25/17
10:55

Gilead participates in a conference call with Leerink

Leerink hosts a conference call with management on May 25 at 11:30 am.

  • 25

    May

GILD Gilead
$64.31

-0.38 (-0.59%)

04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.
04/21/17
PIPR
04/21/17
NO CHANGE
PIPR
Overweight
Piper Jaffray 'encouraged' by Gilead ACC inhibitor data in NASH
Piper Jaffray analyst Joshua Schimmer said Gilead's GS-0976 program in the treatment of NASH are the company's "most interesting" and the just announced data for the ACC inhibitor in a 10 patient study are very encouraging. The analyst, who continues to believe that reducing lipids is a key component for treating NASH, added that long term safety for inhibition of ACC will be necessary before he can have confidence in the program's potential. He keeps an Overweight rating on Gilead shares.
03/20/17
JEFF
03/20/17
NO CHANGE
JEFF
Buy
Jefferies uncovers 'unnoticed' positive NASH data coming from Gilead
Jefferies analyst Brian Abrahams said his review of titles for the upcoming EASL meeting of the International Liver Congress appears to indicate that Gilead's ACC inhibitor GS-0976, which he calls "one of [the company's] least-talked-about assets in NASH," demonstrated significant positive effects in an as-yet-unreported phase 2 study. The analyst, who calls the presentation "unnoticed" and "not broadly discussed," believes the study may meaningfully de-risk a second NASH asset and could set the stage for increasing enthusiasm around Gilead's NASH program over the next 12 months. Abrahams keeps a Buy rating on Gilead shares. The ILC meeting is being held from April 19 to 23 in Amsterdam.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.